Trial Profile
Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Hyperlipidaemia
- Focus Adverse reactions; Biomarker
- 10 Oct 2011 New trial record